---
title: A Phase 2 Trial of Sibeprenlimab in Patients with IgA Nephropathy
date: '2023-11-02'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37916620/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20231103180851&v=2.17.9.post6+86293ac
source: N Engl J Med
description: 'CONCLUSIONS: In patients with IgA nephropathy, 12 months of treatment
  with sibeprenlimab resulted in a significantly greater decrease in proteinuria than
  placebo. (Funded by Visterra; ENVISION ClinicalTrials.gov number, NCT04287985; EudraCT
  number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with IgA nephropathy, 12 months of treatment with sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo. (Funded by Visterra; ENVISION ClinicalTrials.gov number, NCT04287985; EudraCT number, ...